Moderna (NASDAQ: MRNA) has recently received a number of price target changes and ratings updates:
- 11/9/2026 – Moderna had its “overweight” rating reaffirmed by Piper Sandler. They now have a $305.00 price target on the stock, up from $230.00.
- 11/9/2026 – Moderna had its price target raised by The Goldman Sachs Group from $137.00 to $195.00. They now have a “neutral” rating on the stock.
- 10/27/2026 – Moderna was downgraded by William Blair from “outperform” to “market perform”.
- 10/26/2026 – Moderna had its “overweight” rating reaffirmed by Piper Sandler. They now have a $230.00 price target on the stock, up from $167.00.
- 10/23/2026 – Moderna had its “sell” rating reaffirmed by Citigroup.
- 10/21/2026 – Moderna had its “buy” rating reaffirmed by TD Cowen.
- 10/21/2026 – Moderna had its price target raised by TD Cowen from $40.00 to $90.00. They now have a “hold” rating on the stock.
- 10/15/2026 – Moderna had its price target raised by The Goldman Sachs Group from $120.00 to $137.00. They now have a “neutral” rating on the stock.
- 10/9/2026 – Moderna had its price target raised by Bank of America from $170.00 to $200.00. They now have a “neutral” rating on the stock.
- 10/8/2026 – Moderna had its price target raised by Evercore from $50.00 to $80.00.
- 10/7/2026 – Moderna had its price target raised by Morgan Stanley from $89.00 to $95.00. They now have an “equal weight” rating on the stock.
- 9/30/2026 – Moderna was downgraded by Citigroup from “neutral” to “sell”. They now have a $80.00 price target on the stock, up from $60.00.
- 9/25/2026 – Moderna had its “market perform” rating reaffirmed by Sanford C. Bernstein.
- 9/23/2026 – Moderna was upgraded by Singular Research to “hold”.
- 9/22/2026 – Moderna had its “neutral” rating reaffirmed by UBS Group.
Moderna Trading Down 3.6%
Shares of MRNA stock traded down $8.10 during trading hours on Monday, hitting $215.27. 6,997,840 shares of the company were exchanged, compared to its average volume of 12,547,155. The company has a 50 day simple moving average of $201.67 and a two-hundred day simple moving average of $96.41. The firm has a market cap of $87.10 billion, a P/E ratio of -30.32 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $280.80.
Moderna (NASDAQ:MRNA – Get Free Report) last released its earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.51) EPS. Equities analysts anticipate that Moderna, Inc. will post -5.14 EPS for the current year.
Insider Activity
In other news, President Stephen Hoge sold 40,294 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares in the company, valued at $219,921,913.54. This trade represents a 2.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 197,251 shares of company stock worth $33,875,904. Company insiders own 10.80% of the company’s stock.
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Read More
- Five stocks we like better than Moderna
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Moderna Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna Inc and related companies with MarketBeat.com's FREE daily email newsletter.
